Early Use of Novel Biologics in Psoriatic Arthritis: An Evolving Standard of Care

Hear expert insights on when to use interleukin inhibitors in the course of psoriatic arthritis. Review key data on using these novel agents for DMARD-refractory disease with an on-demand expert presentation and focused commentary.

Share

Program Content

Activities

PsA Axial Manifestations
My Take on Treating Axial Manifestations of Psoriatic Arthritis
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: January 11, 2021

Expires: January 10, 2022

Activities

Video: New Biologics in PsA
Early Use of Novel Biologics in Psoriatic Arthritis: An Evolving Standard of Care
Congratulations: You achieved a completion on 04/09/2022
Slides: New Biologics in PsA
Slides on Early Use of Novel Biologics in Psoriatic Arthritis: An Evolving Standard of Care
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 29, 2020

Expires: December 28, 2021

Faculty

cover img faculity

Vinod Chandran, MBBS, MD, DM, PhD

Associate Professor
Consultant Rheumatologist
Division of Rheumatology
Department of Medicine
University of Toronto
University Health Network
Toronto, Canada

cover img faculity

Alexis Ogdie, MD, MSCE

Director, Penn Psoriatic Arthritis and Spondylarthritis Program
Director, Penn Center for Clinical Epidemiology and Biostatistics
University of Pennsylvania
Philadelphia, Pennsylvania

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Novartis Pharmaceuticals Corporation